Episode
Cancer Blood Tests: Are they ready for primetime? Part 1
- Published
- Jun 15, 2026
- Duration seconds
- 2601
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/normal-curves-sexy-science-serious-statistics-7212156/episodes/cancer-blood-tests-are-they-ready-for-primetime-part-1/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/normal-curves-sexy-science-serious-statistics-7212156/cancer-blood-tests-are-they-ready-for-primetime-part-1.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Can a single tube of blood really detect dozens of cancers before symptoms appear? We dive into the science behind Galleri, a blood test that claims to detect more than 50 types of cancer from a simple blood draw. Recent headlines about the test ranged from “breakthrough” to “bust” after the release of results from a massive randomized clinical trial. In this Part 1 episode, we explore cell-free DNA, DNA methylation, machine learning, sensitivity, specificity, and positive predictive value. Along the way, we revisit the prenatal screening revolution, ask why detecting cancer earlier doesn’t always help patients, and learn how escaped DNA convicts end up swimming in a giant molecular pool party. And for the first time ever, Normal Curves ends on a cliffhanger: we’ll save the controversial results of that landmark trial for Part 2. Statistical topics cancer screening case-control studies counterfactuals machine learning negative predictive value overdiagnosis positive predictive value randomized clinical trials screening tests sensitivity and specificity validation References Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies . JAMA . 2015; 314:162-9. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA . Ann Oncol . 2020. 31:745-59. Schrag D, Beer T, McDonnell C et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study . The Lancet . 402: 1251-60. Giridhar KV, et al. Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection test in an intended-use population . Presented at the 2026 American Society of Clinical Oncolo…